Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | HINT1 | P49773 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18198302 | 0.94 | TYMP (0.39) | TYMPHPGDTAS1R3TAS1R1NT5E | |
| SCHEMBL25400771 | 0.90 | TYMP (0.42) | TYMPHPGDTAS1R3TAS1R1NT5E | |
| SCHEMBL15070634 | 0.90 | TYMP (0.42) | TYMPHPGDTAS1R3TAS1R1NT5E | |
| SCHEMBL16375320 | 0.90 | TYMP (0.38) | TYMPHPGDTAS1R3TAS1R1NT5E | |
| SCHEMBL15070715 | 0.89 | TYMP (0.42) | TYMPHPGDTAS1R3TAS1R1NT5E | |
| SCHEMBL25400745 | 0.89 | TYMP (0.42) | TYMPHPGDTAS1R3TAS1R1NT5E | |
| SCHEMBL25399990 | 0.87 | TYMP (0.47) | TYMPHPGDTAS1R3TAS1R1NT5E | |
| SCHEMBL26268385 | 0.87 | TYMP (0.42) | TYMPHPGDTAS1R3TAS1R1NT5E | |
| SCHEMBL15070550 | 0.87 | TYMP (0.42) | TYMPHPGDTAS1R3TAS1R1NT5E | |
| SCHEMBL15070716 | 0.86 | TYMP (0.43) | TYMPHPGDTAS1R3TAS1R1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | TYMP 13/4885HPGD 1338/4885TAS1R3 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.